A detailed history of Bessemer Group Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Bessemer Group Inc holds 733 shares of ASND stock, worth $99,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares
733
Previous 631 16.16%
Holding current value
$99,746
Previous $86,000 26.74%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$113.0 - $153.43 $11,526 - $15,649
102 Added 16.16%
733 $109,000
Q2 2024

Aug 13, 2024

SELL
$121.07 - $153.67 $29,662 - $37,649
-245 Reduced 27.97%
631 $86,000
Q1 2024

May 13, 2024

BUY
$123.45 - $159.4 $40,985 - $52,920
332 Added 61.03%
876 $132,000
Q1 2023

May 10, 2023

BUY
$104.9 - $126.78 $57,065 - $68,968
544 New
544 $58,000
Q2 2022

Aug 10, 2022

SELL
$78.08 - $117.61 $6,090 - $9,173
-78 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$124.92 - $173.33 $9,743 - $13,519
78 New
78 $10,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.59B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.